Arvinas

Pfizer's $1B protein degradation bet yields 3% response rate in Arvinas' midphase breast cancer trial
Pfizer's $1B protein degradation bet yields 3% response rate in Arvinas' midphase breast cancer trial
Fierce Biotech
Pfizer
protein degradation
Arvinas
clinical trials
breast cancer
ARV-471
Flag link:
AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven
AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven
Fierce Biotech
AstraZeneca
Alexion
Arvinas
Connecticut
Flag link:
ASCO-GU – Arvinas sees the path to a prostate cancer niche
ASCO-GU – Arvinas sees the path to a prostate cancer niche
EP Vantage
Arvinas
ARV-110
prostate cancer
ASCO-GU
Flag link:
Licensing deals rack up in 2021
Licensing deals rack up in 2021
EP Vantage
licensing
GSK
Alector
Novartis
BeiGene
Pfizer
Arvinas
iTeos Therapeutics
Bristol Myers Squibb
Eisai
Flag link:
The search for a better Faslodex continues
The search for a better Faslodex continues
EP Vantage
breast cancer
drug development
Serds
Pfizer
Arvinas
Flag link:
Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table
Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table
Fierce Biotech
Pfizer
Arvinas
breast cancer
protein degradation
biobucks
Flag link:
ASCO: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer
ASCO: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer
Fierce Biotech
ASCO 2020
Arvinas
ARV-110
protein degradation
prostate cancer
Flag link:
2 Biotech Stocks That Soared Last Week
2 Biotech Stocks That Soared Last Week
Motley Fool
Biogen
Arvinas
aducanumab
protein degradation
ARV-110
Flag link:
Big Pharma Bets on Body’s Garbage-Disposal System to Beat Cancer
Big Pharma Bets on Body’s Garbage-Disposal System to Beat Cancer
Bloomberg
cancer
Arvinas
Kymera
targeted protein degradation
Flag link:
Bayer inks Arvinas deal to develop protein degraders
Bayer inks Arvinas deal to develop protein degraders
Fierce Biotech
Bayer
Arvinas
targeted protein degradation
Flag link:
Nasdaq triple IPO play brings in $345M as the big biotech party rocks on
Nasdaq triple IPO play brings in $345M as the big biotech party rocks on
Endpoints
NASDAQ
IPOs
Entasis
Urovant Sciences
Arvinas
Sutro BioPharma
Flag link:
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs
Xconomy
biotech
IPOs
Sutro BioPharma
Arvinas
cancer
Flag link:
Pfizer lines up an $830M alliance with Arvinas on protein degradation
Pfizer lines up an $830M alliance with Arvinas on protein degradation
Endpoints
Pfizer
Arvinas
targeted protein degradation
drug development
Flag link:
Genentech inks $650M deal with protein degradation pioneer Arvinas
Genentech inks $650M deal with protein degradation pioneer Arvinas
Endpoints
Genentech
targeted protein degradation
Arvinas
R&D
Flag link:
From big biopharma to biotech CEO, John Houston’s R&D journey highlights a fast-changing world
From big biopharma to biotech CEO, John Houston’s R&D journey highlights a fast-changing world
Endpoints
R&D
John Houston
Big Pharma
biotech
Arvinas
GSK
Bristol-Myers Squibb
Flag link:
The 2015 Fierce 15 biotech execs take a bow
The 2015 Fierce 15 biotech execs take a bow
Fierce Biotech
Alector
Arvinas
CRISPR Therapeutics
Intellia Therapeutics
NGM Biopharmaceuticals
Padlock Therapeutics
SQZ Biotech
Revolution Medicines
Syros Pharmaceuticals
Unum Therapeutics
Yumanity Therapeutics
Flag link:
FierceBiotech's 2015 Fierce 15
FierceBiotech's 2015 Fierce 15
Fierce Biotech
Alector
Arvinas
Cell Medica
CRISPR Therapeutics
Denali Therapeutics
Intellia Therapeutics
MyoKardia
NGM Biopharmaceuticals
Padlock Therapeutics
Revolution Medicines SQZ Biotech
Surface Oncology
Syros Pharmaceuticals
Unum Therapeutics
Yumanity Therapeutics
Flag link:
Merck wagers $434M on Arvinas and its protein-disposal system
Merck wagers $434M on Arvinas and its protein-disposal system
Fierce Biotech
Merck
Arvinas
protein disposal
Flag link: